Axsome Therapeutics begins CLARITY Phase 3 trial of solriamfetol in adults with major depressive disorder and excessive daytime sleepiness

Axsome Therapeutics has initiated the CLARITY Phase 3 trial studying solriamfetol in adults with major depressive disorder who experience excessive daytime sleepiness; the company's press release includes standard forward-looking statements and associated risks.

Axsome Therapeutics announced the start of the CLARITY Phase 3 clinical trial. The trial tests solriamfetol in adults diagnosed with major depressive disorder who report excessive daytime sleepiness. The company’s press release also included standard forward-looking statements and risk disclosures. Key facts: - Axsome has initiated the CLARITY Phase 3 trial for solriamfetol. - The study population is described as adults with major depressive disorder and excessive daytime sleepiness symptoms. - The press release included customary forward-looking language and referenced the company’s other products, including SUNOSI, AUVELITY, and SYMBRAVO. Summary: The announcement marks a new phase in Axsome’s clinical program for solriamfetol in this patient group. Timelines for enrollment, interim results, or regulatory submissions were not specified. Undetermined at this time.